Posted by Michael Wonder on 20 May 2021
NICE turns down Janssen's Erleada
20 May 2021 - NICE has published draft guidance rejecting Janssen's Erleada (apalutamide) with androgen deprivation therapy for treating prostate cancer.
The draft guidance considers Erleada for treating hormone-relapsed prostate cancer in adults who are at high risk of the cancer spreading, or hormone-sensitive prostate cancer that has already metastasised.
